Prediction of response to anti-TNF treatment using laboratory biomarkers in patients with rheumatoid arthritis: a systematic review

Autor: Alfons A den Broeder, Paco M J Welsing, Bart J F van den Bemt, Lise M Verhoef, Maike H M Wientjes

Publikováno v: RMD Open, Vol 8, Iss 2 (2022)

Objectives In this systematic review, we aim to identify laboratory biomarkers that predict response to tumour necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA).Methods EMBASE, PubMed and Cochrane Library (CENTRAL) were sea

Externí odkaz: https://doaj.org/article/76659779552b436f994c57bf80320a8c

The added value of predictive biomarkers in treat-to-target strategies for rheumatoid arthritis patients: a conceptual modelling study

Autor: Maike H M Wientjes, Evy Ulijn, Wietske Kievit, Robert B M Landewé, Inger Meek, Nathan den Broeder, Noortje van Herwaarden, Bart J F van den Bemt, Lise M Verhoef, Alfons A den Broeder

Publikováno v: Rheumatology (Oxford, England).

Objectives To quantify the additional value of a hypothetical biomarker predicting response to treatment for RA regarding efficacy and costs by using a modelling design. Methods A Markov model was built comparing a usual care T2T strategy with a biom

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a57236e82a9b68779d658d7ee6afe59
https://pubmed.ncbi.nlm.nih.gov/36538875

Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial

Autor: Theo Rispens, Ronald F. van Vollenhoven, Annick de Vries, Gerrit Jan Wolbink, Maarten Boers, Alfons A den Broeder, Michael T. Nurmohamed, Sadaf Atiqi, Maike H. M. Wientjes, Bart J F van den Bemt

Publikováno v: Trials, 22
Trials, Vol 22, Iss 1, Pp 1-9 (2021)
Wientjes, M H M, Atiqi, S, Wolbink, G J, Nurmohamed, M T, Boers, M, Rispens, T, de Vries, A, van Vollenhoven, R F, van den Bemt, B J F & den Broeder, A A 2021, ' Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch) : study protocol for a fully blinded randomised superiority test-treatment trial ', Trials, vol. 22, no. 1, 406, pp. 406 . https://doi.org/10.1186/s13063-021-05358-7
Trials, 22(1):406. BioMed Central
Trials, 22, 1
Trials

Background A substantial proportion of rheumatoid arthritis (RA) patients discontinues treatment with tumour necrosis factor inhibitors (TNFi) due to inefficacy or intolerance. After the failure of treatment with a TNFi, treatment can be switched to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2b7b62fca21fbdfa4dd2b20782e46d8
https://doi.org/10.1186/s13063-021-05358-7

Clinical utility of therapeutic drug monitoring in biological disease modifying anti-rheumatic drug treatment of rheumatic disorders: a systematic narrative review

Autor: Maike H. M. Wientjes, Bart J F van den Bemt, Cornelis Kramers, Noortje van Herwaarden, Alfons A den Broeder

Publikováno v: Expert Opinion on Drug Metabolism & Toxicology, 13, 843-857
Expert Opinion on Drug Metabolism & Toxicology, 13, 8, pp. 843-857

Item does not contain fulltext INTRODUCTION: Biological Disease Modifying Anti-Rheumatic Drugs (bDMARDs) have improved the treatment outcomes of inflammatory rheumatic diseases including Rheumatoid Arthritis and spondyloarthropathies. Inter-individua

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b48821637cb6ef8a92a2d8a9b855eaf9
https://hdl.handle.net/2066/176979

Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial

Autor: Maike H. M. Wientjes, Sadaf Atiqi, Gerrit Jan Wolbink, Michael T. Nurmohamed, Maarten Boers, Theo Rispens, Annick de Vries, Ronald F. van Vollenhoven, Bart J. F. van den Bemt, Alfons A. den Broeder

Publikováno v: Trials, Vol 22, Iss 1, Pp 1-9 (2021)

Abstract Background A substantial proportion of rheumatoid arthritis (RA) patients discontinues treatment with tumour necrosis factor inhibitors (TNFi) due to inefficacy or intolerance. After the failure of treatment with a TNFi, treatment can be swi

Externí odkaz: https://doaj.org/article/469fd6c7ea734e45953465a9681f5bdb